Microbial models of mammalian metabolism: Fungal metabolism of phenolic and nonphenolic p-cymene-related drugs and prodrugs. I. Metabolites of thymoxamine

Drug Metabolism and Disposition

Volumn 25, Issue 3, 1997, Pages 301-310

  Moussa, Cecile ^b   Houziaux, Patrick ^b   Danree, Bernard ^b   Azerad, Robert ^a  

^a CNRS   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

[4 (2 DIMETHYLAMINOETHOXY) 5 ISOPROPYL 2 METHYLPHENYL] 1 BETA D GLUCOPYRANOSIDE 7; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DESACETYLTHYMOXAMINE O SULFATE 6; MOXISYLYTE DERIVATIVE; NORDESACETYLTHYMOXAMINE 3; PHENOL DERIVATIVE; THYMOXAMINE 1; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; BIOTRANSFORMATION; DRUG ELIMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG PURIFICATION; FUNGUS GROWTH; GLYCOSYLATION; HYDROLYSIS; PRIORITY JOURNAL; REACTION ANALYSIS; STRAIN DIFFERENCE;

ADRENERGIC ALPHA-ANTAGONISTS; BIOTRANSFORMATION; DRUG EVALUATION, PRECLINICAL; FUNGI; MOXISYLYTE; PRODRUGS;

ACTINOMUCOR ELEGANS; AMYLOMYCES ROUXII; ANIMALIA; FUNGI; MAMMALIA; MORTIERELLA; MUCOR; MUCOR HIEMALIS; UMBELOPSIS ISABELLINA;

EID: 0030942460     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. A. T. Birmingham and J. Szolcsanyi: Competitive blockade of adrenergic receptors and histamine receptors by thymoxamine. J. Pharm. Pharmacol. 17, 449-458 (1965).
2. L. Fawke: Is thymoxamine a specific alpha-adrenoceptor blocking agent? Br. J. Pharmacol. 44, 362P-363P (1972).
3. G. M. Drew: Effects of alpha-adrenoceptor agonists and antagonists on pre- and postsynaptically located alpha-adrenoceptors. Eur. J. Pharmacol. 36, 313-320 (1976).
4. M. H. Creuzet, G. Prat, A. Malek, F. Fauran, and J. Roquebert: In vitro and in vivo α-blocking activity of thymoxamine and its two metabolites. J. Pharm. Pharmacol. 32,209-213 (1980).
5. R. W. Foster: The nature of the adrenergic receptors of the trachea of the guinea pig. J. Pharm. Pharmacol. 18, 1-12 (1966).
6. M. Poirier, J. P. Riffaud, J. Y. Lacolle, and C. Dupont: Effects of five alpha-blockers on the hypogastric nerve stimulation of the canine lower urinary tract. J. Urol. 140, 165-167 (1988).
7. J. P. Riffaud: Recherche biochimique et pharmacologique de nouveaux alpha-bloquants urosélectifs. J.A.M.A. (Suppl. French Ed.) 9-12 (Jan. 1992).
8. K. Watanabe, Y. Hayashi, K. Ikeda, and H. Ohnishi: Effect of moxisylyte on the lower urinary tract. 1. Effect on the isolated rabbit urethra and bladder. Folia Pharmacol. Jpn. 97, 145-151 (1991).
9. K. Watanabe, Y. Hayashi, K. Ikeda, and H. Ohnishi: Effect of moxisylyte on the lower urinary tract. 2. Effect on the urethra in anesthetized dogs. Folia Pharmacol. Jpn. 97, 153-165 (1991).
10. A. Zaroli, S. Bernasconi, and P. Bossi: Effet d'un medicament alpha-lytique (thymoxamine) sur le profil des pressions de l'urètre. Arch. Ital. Neurol. Nefrol. 51, 281-289 (1979).
11. C. Feniou, B. Neau, G. Prat, C. Cheze, F. Fauran, and J. Roquebert: Metabolism of thymoxamine: identification of metabolites in rat. J. Pharm. Pharmacol. 32, 104-107 (1980).
12. F. Nielsen-Kudsk, P. Jakobsen, and I. Magnussen: Plasma induced biotransformation of thymoxamine and its kinetics. Acta Pharmacol. Toxicol. 47, 11-16 (1980).
13. 14C-thymoxamine in rats. Eur. J. Drug Metab. Pharmacokinet. 10, 61-69 (1985).
14. 14C-thymoxamine in man. Eur. J. Drug Metab. Pharmacokinet. 10, 71-76 (1985).
15. K.-O. Vollmer and A. VonHodenberg: Metabolism of thymoxamine. III. Structure elucidation of the metabolites and interspecies comparison. Eur. J. Drug Metab. Pharmacokinet. 10, 139-145 (1985).
16. 14C-thymoxamine in rat and man. Xenobiotica 18, 919-928 (1988).
17. C. Marquer, J. H. Trouvin, J. Y. Lacolle, C. Dupont, and C. Jacquot: Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 16, 183-188 (1991).
18. R. V. Smith and J. P. Rosazza: Microbial models of mammalian metabolism. Aromatic hydroxylation. Arch. Biochem. Biophys. 161, 551-558 (1974).
19. R. V. Smith and J. P. Rosazza: Microbial models of mammalian metabolism. J. Pharm. Sci. 11, 1737-1759 (1975).
20. R. J. P. Cannell, A. R. Knaggs, M. J. Dawson, G. R. Manchee, P. J. Eddershaw, I. Waterhouse, D. R. Sutherland. G. D. Bowers, and P. J. Sidebottom: Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite. Drug Metab. Dispos. 23, 724-729 (1995).
21. C. E. Cerniglia, J. P. Freeman, and R. K. Mitchum: Glucuronide and sulfate conjugation in the fungal metabolism of aromatic hydrocarbons. Appl. Environ. Microbiol. 43, 1070-1075 (1982).
22. T. S. Chen, L. So, R. White, and R. L. Monaghan: Microbial hydroxylation and glucuronidation of the angiotensin-II (AII) receptor antagonist MK-954. J. Antibiot. 46, 131-134 (1993).
23. K. Petzoldt, K. Kieslich, and H. Steinbeck (Schering AG): Oestratriene 3-beta glucosides preparation by adding 3-hydroxy steroid to a carbohydrate-containing fungal culture medium. German Patent 2,326,084 (19 May 1973), C.A. 82, 86566s (1975).
24. K. Kieslich, H.-J. Vidic, K. Petzoldt, and G. A. Hoyer: Microbiologische Umwandlungen nichsteroider Strukturen. VII. Mikrobielle Glucosidierung einer phenolischen Hydroxylgruppe. Chem. Ber. 109, 2259-2265 (1976).
25. G. Neef, U. Eder, K. Petzoldt, A. Seeger, and P. Wieglepp: Microbial hydroxylations of β-carboline derivatives. J. Chem. Soc. Chem. Commun. 366 (1982).
26. M. S. Raju, G. S. Wu, A. Gard, and J. P. Rosazza: Microbial transformations of natural antitumor agents. 20. Glucosylation of viridicatum toxin. J. Natl. Prod. 45, 321-327 (1982).
27. H. Kamimura: Conversion of zearalenone to zearalenone glycoside by Rhizopus sp. Appl. Environ. Microbiol. 52, 515-519 (1986).
28. B. Vigne, A. Archelas, J.-D. Fourneron, and R. Furstoss: Microbial transformations. Part 4(1). Regioselective para hydroxylation of aromatic rings by the fungus Beauveria sulfurescens. The metabolism of isopropyl N-phenyl carbamate (Propham®). Tetrahedron 42, 2451-2456 (1986).
29. S. ElSharkawy and Y. J. AbulHajj: Microbial transformation of zearalenone. I. Formation of zearalenone-4-O-β-glucoside. J. Natl. Prod. 50. 520-521 (1987).
30. M. Hezari and P. J. Davis: Microbial models of mammalian metabolism. Furosemide glucoside formation using the fungus Cunninghamella elegans. Drug Metab. Dispos. 21, 259-267 (1993).
31. S. H. ElSharkawy and Y. J. AbulHajj: Microbial transformation of zearalenone. 2. Reduction, hydroxylation and methylation products. J. Org. Chem. 53, 515-519 (1988).
32. S. H. ElSharkawy: Microbial transformation of zearalenone. III. Formation of 2,4-O-β-diglucoside. Acta Pharm. Jugosl. 39, 303-310 (1989).
33. S. H. ElSharkawy, M. I. Selim, M. S. Afifi, and F. T. Halaweish: Microbial transformation of zearalenone to a zearalenone sulfate. Appl. Environ. Microbiol. 57, 549-552 (1991).
34. A. Ibrahim and Y. J. AbulHajj: Microbial transformation of flavonoids: sulfation of 5-hydroxyflavone by Streptomyces fulvissimus. Appl. Environ. Microbiol. 55, 3140-3142 (1989).
35. B. C. Foster, B. H. Thomas, J. Zamecnik, B. A. Dawson, D. L. Wilson, R. Duhaime, G. Solomonraj, I. J. McGilveray, and B. A. Lodge: Aromatic hydroxylation and sulfation of phenazopyridine by Cunninghamella echinulata. Can. J. Microbiol. 37, 504-508 (1991).
36. D. Liotta, J. Arbiser, J. W. Short, and M. Saindane: A simple, inexpensive procedure for the large scale production of alkyl quinones. J. Org. Chem. 48, 2932-2933 (1983).
37. R. D. Stolow, P. M. McDonagh, and M. M. Bonaventura: Conformational studies. VI. Intramolecular hydrogen bonding in non-chair conformations of cis,cis,cis-2,5-dialkyl-1,4-cyclohexanediols. J. Am. Chem. Soc. 86, 2165-2170 (1964).
38. K. Mori, M. Tominaga, T. Takigawa, and M. Matsui: A mild transesterification method. Synthesis 790-791 (1973).
39. E. Zavarin and A. B. Anderson: Extractive components from incensecedar heartwood (Libocedrus decurrens Torrey). II. Occurrence and synthesis of p-methoxythymol and p-methoxycarvacrol, two new phenolic compounds. J. Org. Chem. 20, 443-447 (1955).
40. S. Shigenaga, I. Kouno, and N. Kawano: Triterpenoids and glycosides from Geum japonicum. Phytochemistry 24, 115-118 (1985).
41. A. Flores-Carreon and S. Bartnicki-Garcia: Polyuronide biosynthesis by cell free extracts of Mucor rouxii. J. Gen. Microbiol. 128, 2023-2027 (1982).
42. C. A. Marsh and G. A. Levvy: The synthesis of aryl glycosiduronic acids. Biochem. J. 68, 617-621 (1958).
43. N. J. Davis and S. L. Flitsch: Selective oxidation of monosaccharide derivatives to uronic acids. Tetrahedron Lett. 34, 1181-1184 (1993).
44. T. Vial, N. Stremdoerfer, L. Ollivier, B. Veyre, G. Goujon, M. Pelletier, and T. Fontanges: Un cas d'hépatite aiguë au chlorhydrate de moxisylyte. Gastroenterol. Clin. Biol. 15, 95-96 (1991).
45. D. Larrey: Découverte tardive de l'hépatotoxicité des médicaments. Gastroenterol. Clin. Biol. 15, 875 (1991).
46. A. Levy-Bruhl, J. Germanaud, D. Gargot, and J.-L. Legoux: Une hépatite cytolytique au moxisylyte? Gastroenterol. Clin. Biol. 15, 979 (1991).
47. G. Mignot, G. Dumas, R. M. Chichmanian, and A. Spreux: Moxisylyte: atteinte hépatique. Un cas avec réadministration positive. Gastroenterol. Clin. Biol. 15, 979-980 (1991).
48. V. Ratziu, T. Poynard, H. Sabah, S. Naveau, and J.-C. Chaput: Hépatotoxicité du chlorhydrate de moxisylyte: un nouveau cas. Gastroenterol. Clin. Biol. 15, 980 (1991).
49. K. Öllinger and A. Brunmark: Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J. Biol. Chem. 266, 21496-21503 (1991).
50. P. J. O'Brien: Molecular mechanisms of quinone cytotoxicity. Chem.-Biol. Interact. 67, 129-138 (1991).
51. S. A. Akman, M. Dietrich, R. Chlebowski, P. Limberg, and J. B. Block: Modulation of cytotoxicity of menadione sodium bisulfite versus leukemia L1210 by the acid-soluble thiol pool. Cancer Res. 45, 5257-5262 (1985).
52. C. R. Stubberfield and G. M. Cohen: Interconversion of NAD(H) to NADP(H). A cellular response to quinone-induced oxidative stress in isolated hepatocytes. Biochem. Pharmacol. 38, 2631-2637 (1989).
53. L. Rossi, G. A. Moore, S. Orrenius, and P. J. O'Brien: Quinone toxicity in hepatocytes without oxidative stress. Arch. Biochem. Biophys. 251, 25-35 (1986).
54. P. Workman: Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol. Res. 6, 461-475 (1994).
55. H. D. Beall, A. M. Murphy, D. Siegel, R. H. J. Hargreaves, J. Butler, and D. Ross: Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol. Pharmacol. 48, 499-504 (1995).
56. Z. Djuric, T. H. Corbett, F. A. Valeriote, L. K. Heilbrun, and L. H. Baker: Detoxification ability and toxicity of quinones in mouse and human cell lines used for anticancer drug screening. Cancer Chemother. Pharmacol. 36, 20-26 (1995).
57. J. W. Gorrod and L. A. Damani (ed.): Biological oxidation of nitrogen in organic molecules. In "Ellis Horwood Health Science Series" (A. Wiseman, ed.), pp. 445. Ellis Horwood & VCH, Chichester, 1985.